Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and hepatocellular carcinoma by offering better clinical responses. However, sorafenib and sunitinib are commonly associated with cutaneous toxicity. OBJECTIVES: We conducted this study to make a clinical assessment of the cutaneous toxicities induced by the oral multitargeted kinase inhibitors sorafenib and sunitinib. METHODS: Retrospectively, we reviewed medical records of patients receiving multitargeted kinase inhibitors, including 109 patients on sorafenib for the treatment of renal cell carcinoma or hepatocellular carcinoma and 119 patients receiving sunitinib for treatment of renal cell carcinoma or a gastrointestinal stromal tumour. Clinical data on cutaneous toxicities were collated. We describe the incidences and intensities of toxicities, and analyse the data statistically. RESULTS: The most common cutaneous toxicity was hand-and-foot skin reaction (HFSR). Other cutaneous toxicities included alopecia, stomatitis, skin discoloration (hair or face), subungual splinter haemorrhage, facial swelling, facial erythema and xerosis. HFSR and severe stomatitis required therapy modifications to relieve symptoms, but other cutaneous toxicities did not affect treatment course. HFSR was observed in 48% of patients treated with sorafenib and 36% of those treated with sunitinib. Median time to onset was 18.4 days in patients receiving sorafenib and 32.4 days in those receiving sunitinib. HFSR and stomatitis were early symptoms compared with other cutaneous toxicities. Patients with severe HFSR were likely to develop the symptoms at early phases of therapy. A significant correlation between the severity of HFSR and development of alopecia and stomatitis was found. CONCLUSIONS: Multitargeted kinase inhibitors are associated with a significant risk of various cutaneous adverse events. HFSR is the commonest and most serious cutaneous toxicity in patients treated with these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J.-C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Wechsler, J., Lhomme, C., Escudier, B., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 554
BAY 43-9006 Inhibition of Oncogenic RET Mutants
Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 476
Lacouture, M. E., Wu, S., Robert, C., Atkins, M. B., Kong, H. H., Guitart, J., Garbe, C., Hauschild, A., Puzanov, I., Alexandrescu, D. T., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0131 · Cited by 337
Raf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
Lacouture, M. E., Reilly, L. M., Gerami, P., & Guitart, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn389 · Cited by 255
SCF/c‐kit signaling is required for cyclic regeneration of the hair pigmentation unit
BOTCHKAREVA, N. V., KHLGATIAN, M., JACK LONGLEY, B., BOTCHKAREV, V. A., & GILCHREST, B. A. (2001) · The FASEB Journal · doi:10.1096/fj.00-0368com · Cited by 247
Bhojani, N., Jeldres, C., Patard, J.-J., Perrotte, P., Suardi, N., Hutterer, G., Patenaude, F., Oudard, S., & Karakiewicz, P. I. (2008) · European Urology · doi:10.1016/j.eururo.2007.11.037 · Cited by 239
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
Chu, D., Lacouture, M. E., Fillos, T., & Wu, S. (2008) · Acta Oncologica · doi:10.1080/02841860701765675 · Cited by 197
Yang, C.-H., Lin, W.-C., Chuang, C.-K., Chang, Y.-C., Pang, S.-T., Lin, Y.-C., Kuo, T.-T., Hsieh, J.-J., & Chang, J. W. C. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08357.x · Cited by 182
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
Robert, C., Mateus, C., Spatz, A., Wechsler, J., & Escudier, B. J. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.034 · Cited by 154
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
Rosenbaum, S. E., Wu, S., Newman, M. A., West, D. P., Kuzel, T. M., & Lacouture, M. E. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0409-1 · Cited by 112
Imatinib Mesylate and Gray Hair
Étienne, G., Cony‐Makhoul, P., & Mahon, F. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470614 · Cited by 95
Sorafenib-Induced Eruptive Melanocytic Lesions
Kong, H. H., Sibaud, V., Turner, M. L. C., Fojo, T., Hornyak, T. J., & Chevreau, C. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.6.820 · Cited by 83
Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Moss, K. G., Toner, G. C., Cherrington, J. M., Mendel, D. B., & Laird, A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052530 · Cited by 82
Expression of c-kit ligand in human keratinocytes
Morita, E., Lee, D., Sugiyama, M., & Yamamoto, S. (1994) · Archives of Dermatological Research · doi:10.1007/bf00387600 · Cited by 49
Hand-Foot and Stump Syndrome to Sorafenib
Lai, S. E., Kuzel, T., & Lacouture, M. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9565 · Cited by 47
Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab
Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Annunziata, C. M., Barrett, T., Premkumar, A., Kotz, H. L., Sarosy, G., Minasian, L. M., & Kohn, E. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3004 · Cited by 42
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
Cinausero, M., Aprile, G., Ermacora, P., Basile, D., Vitale, M. G., Fanotto, V., Parisi, G., Calvetti, L., & Sonis, S. T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00354 · Cited by 290
Cutaneous adverse effects of targeted therapies
Macdonald, J. B., Macdonald, B., Golitz, L. E., LoRusso, P., & Sekulic, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.032 · Cited by 237
Fostering a healthy culture: Biological relevance of in vitro and ex vivo skin models
Atwood, S. X., & Plikus, M. V. (2021) · Experimental Dermatology · doi:10.1111/exd.14296 · Cited by 15
Metadata
- Authors
- Lee, W. J., Lee, J. L., Chang, S. E., Lee, M. W., Kang, Y. K., Choi, J. H., Moon, K. C., & Koh, J. K.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11
- Volume
- 161
- Issue
- 5
- Pages
- 1045-1051
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W1993561468
- Cited by
- 237
- References
- 24
- FWCI
- 22.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.